| scholarly article | Q13442814 |
| P50 | author | Colin Rae | Q57628906 |
| P2093 | author name string | Colin Nixon | |
| Andreas Hock | |||
| Mathias Tesson | |||
| Richa Vasan | |||
| Mark Gaze | |||
| Robert Mairs | |||
| P2860 | cites work | PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints | Q24527393 |
| Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma | Q39505317 | ||
| Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma | Q39596829 | ||
| MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response. | Q39617806 | ||
| New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome | Q39639490 | ||
| Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage | Q39790130 | ||
| A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. | Q40160733 | ||
| [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter | Q40352960 | ||
| Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma | Q40619458 | ||
| Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line | Q40825639 | ||
| Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging | Q40913291 | ||
| Growth and characterization of LNCaP prostate cancer cell spheroids | Q40920874 | ||
| Characterization of somatostatin receptors on human neuroblastoma tumors. | Q41500083 | ||
| Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity | Q41561051 | ||
| Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan | Q41733479 | ||
| Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models | Q43376054 | ||
| Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. | Q45947406 | ||
| Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. | Q45972216 | ||
| Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro | Q46252964 | ||
| Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma | Q46470457 | ||
| Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival | Q46735215 | ||
| Cytoskeletal interference - A new mode of action for the anticancer drugs camptothecin and topotecan | Q47863538 | ||
| Identification, characterization, and biological activity of somatostatin receptors in human neuroblastoma cell lines. | Q52384283 | ||
| Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. | Q53634741 | ||
| A simplified method for production and growth of multicellular tumor spheroids | Q67684815 | ||
| The relationship between tumour geometry and the response of tumour cells to cytotoxic drugs--an in vitro study using EMT6 multicellular spheroids | Q70110627 | ||
| Low frequency of the p53 gene mutations in neuroblastoma | Q72496549 | ||
| Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome | Q73148522 | ||
| Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction | Q77556300 | ||
| Chemical Variations on the p53 Reactivation Theme | Q26749008 | ||
| In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 | ||
| Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization | Q27670558 | ||
| MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53. | Q27853125 | ||
| Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up | Q27853350 | ||
| The inhibition of autophagy sensitises colon cancer cells with wild-type p53 but not mutant p53 to topotecan treatment | Q28483781 | ||
| Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas | Q29616243 | ||
| Restoration of p53 function leads to tumour regression in vivo | Q29618727 | ||
| Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). | Q31777917 | ||
| Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage | Q31885912 | ||
| 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma | Q33395827 | ||
| Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. | Q33439682 | ||
| High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma | Q33743767 | ||
| Modeling the therapeutic efficacy of p53 restoration in tumors | Q34593294 | ||
| Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP | Q35011473 | ||
| Wild type p53 reactivation: from lab bench to clinic. | Q35146343 | ||
| Expressions of Somatostatin Receptor Subtypes (SSTR-1, 2, 3, 4 and 5) in Neuroblastic Tumors; Special Reference to Clinicopathological Correlations with International Neuroblastoma Pathology Classification and Outcomes | Q35288725 | ||
| Nutlin-3 down-regulates retinoblastoma protein expression and inhibits muscle cell differentiation | Q35681140 | ||
| The p53 tumor suppressor participates in multiple cell cycle checkpoints | Q36495323 | ||
| Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells. | Q37480094 | ||
| Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis. | Q37518896 | ||
| Preclinical Assessment of Strategies for Enhancement of Metaiodobenzylguanidine Therapy of Neuroendocrine Tumors | Q37908692 | ||
| Molecular mechanisms of somatostatin receptor trafficking | Q37967158 | ||
| Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma | Q38087832 | ||
| A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma | Q38170852 | ||
| Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. | Q38354018 | ||
| Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters | Q38559192 | ||
| Peptide receptor radionuclide therapy of neuroendocrine tumours | Q38772485 | ||
| Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs | Q38773634 | ||
| Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity | Q38845519 | ||
| The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer | Q38858580 | ||
| Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma | Q38890690 | ||
| Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma | Q38985584 | ||
| Immunocytochemical localization of somatostatin receptor sst2A in the rat spinal cord and dorsal root ganglia | Q39442481 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 49 | |
| P921 | main subject | neuroblastoma | Q938205 |
| lutetium-177 | Q18882670 | ||
| P304 | page(s) | 29082-29096 | |
| P577 | publication date | 2018-06-26 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma | |
| P478 | volume | 9 |
Search more.